A phase 2, multicenter, open-label study of CNTO 328 (anti-IL-6 monoclonal antibody) in combination with mitoxantrone versus mitoxantrone in subjects with metastatic hormone-refractory prostate cancer (HRPC)

Trial Profile

A phase 2, multicenter, open-label study of CNTO 328 (anti-IL-6 monoclonal antibody) in combination with mitoxantrone versus mitoxantrone in subjects with metastatic hormone-refractory prostate cancer (HRPC)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Sep 2016

At a glance

  • Drugs Siltuximab (Primary) ; Mitoxantrone; Prednisone
  • Indications Prostate cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors Centocor
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Jun 2012 Company added in the association field as reported by EudraCT.
    • 29 Jun 2012 Additional trial location (Germany) identified as reported by EudraCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top